AstraZeneca-Ionis Heart Drug Wainua Fails Late-Stage Trial Main Goal
IONS has more than doubled off its 52-week low of $40.03.
Summary
The AstraZeneca-Ionis partnered drug, Wainua, failed to meet its primary endpoint in a late-stage trial for heart disease, specifically in reducing cardiovascular deaths and recurring heart problems. This is a significant setback for Ionis, as late-stage drug failures represent a loss of substantial R&D investment and potential future revenue. The news contrasts sharply with a recent series of positive developments for Ionis, including strong Q1 results, multiple positive clinical readouts, and an FDA approval for TRYNGOLZA, which had driven the stock near its 52-week high.
At the time of this announcement, IONS was trading at $86.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14B. The 52-week trading range was $40.03 to $86.74. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.